This is a preview of subscription content, log in via an institution to check access.
Notes
2019 Japanese yen
Reference
Yamazaki K, et al. Budget impact analysis of treatment-free remission in nilotinib-treated Japanese chronic myeloid leukemia patients. Cancer Science 111: 2526-2535, No. 7, Jul 2020. Available from: URL: http://doi.org/10.1111/cas.14430
Rights and permissions
About this article
Cite this article
Economic impact of stopping nilotinib in patients with CML in remission. PharmacoEcon Outcomes News 861, 15 (2020). https://doi.org/10.1007/s40274-020-7097-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-7097-6